248 related articles for article (PubMed ID: 1642640)
1. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver.
Walton MI; Wolf CR; Workman P
Biochem Pharmacol; 1992 Jul; 44(2):251-9. PubMed ID: 1642640
[TBL] [Abstract][Full Text] [Related]
2. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
Riley RJ; Hemingway SA; Graham MA; Workman P
Biochem Pharmacol; 1993 Mar; 45(5):1065-77. PubMed ID: 8461036
[TBL] [Abstract][Full Text] [Related]
3. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
Walton MI; Workman P
Biochem Pharmacol; 1990 Jun; 39(11):1735-42. PubMed ID: 2344370
[TBL] [Abstract][Full Text] [Related]
4. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
Fitzsimmons SA; Lewis AD; Riley RJ; Workman P
Carcinogenesis; 1994 Aug; 15(8):1503-10. PubMed ID: 8055626
[TBL] [Abstract][Full Text] [Related]
5. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins.
Walton MI; Wolf CR; Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):983-6. PubMed ID: 2703406
[TBL] [Abstract][Full Text] [Related]
6. Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines.
Cahill A; White IN
Carcinogenesis; 1990 Aug; 11(8):1407-11. PubMed ID: 2117504
[TBL] [Abstract][Full Text] [Related]
7. One-electron reductive bioactivation of 2,3,5,6-tetramethylbenzoquinone by cytochrome P450.
Goeptar AR; te Koppele JM; van Maanen JM; Zoetemelk CE; Vermeulen NP
Biochem Pharmacol; 1992 Jan; 43(2):343-52. PubMed ID: 1310854
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
Wang J; Biedermann KA; Wolf CR; Brown JM
Br J Cancer; 1993 Feb; 67(2):321-5. PubMed ID: 8431360
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of two classes of azo dye reductase activity associated with rat liver microsomal cytochrome P450.
Zbaida S; Levine WG
Biochem Pharmacol; 1990 Dec; 40(11):2415-23. PubMed ID: 2125221
[TBL] [Abstract][Full Text] [Related]
10. Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase.
Barham HM; Stratford IJ
Biochem Pharmacol; 1996 Mar; 51(6):829-37. PubMed ID: 8602879
[TBL] [Abstract][Full Text] [Related]
11. Involvement of a cytochrome P450 system in microsomal debromination of alpha-(bromisovaleryl)urea.
Oka K; Kitamura S; Tatsumi K
J Pharm Pharmacol; 1996 Sep; 48(9):930-2. PubMed ID: 8910855
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton MI; Workman P
J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
[TBL] [Abstract][Full Text] [Related]
13. Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH:cytochrome p450 reductase.
Arlt VM; Stiborova M; Hewer A; Schmeiser HH; Phillips DH
Cancer Res; 2003 Jun; 63(11):2752-61. PubMed ID: 12782579
[TBL] [Abstract][Full Text] [Related]
14. Cyclic conversion of the novel Src kinase inhibitor [7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) and Its N-oxide metabolite by flavin-containing monoxygenases and cytochrome P450 reductase.
Kousba A; Soll R; Yee S; Martin M
Drug Metab Dispos; 2007 Dec; 35(12):2242-51. PubMed ID: 17881660
[TBL] [Abstract][Full Text] [Related]
15. Participation of cytochrome P-450 in reductive metabolism of 1-nitropyrene by rat liver microsomes.
Saito K; Kamataki T; Kato R
Cancer Res; 1984 Aug; 44(8):3169-73. PubMed ID: 6430544
[TBL] [Abstract][Full Text] [Related]
16. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
Patterson AV; Barham HM; Chinje EC; Adams GE; Harris AL; Stratford IJ
Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
[TBL] [Abstract][Full Text] [Related]
17. In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes.
Zhang Y; Guo X; Lin ET; Benet LZ
Pharmacology; 1999 Mar; 58(3):147-59. PubMed ID: 9925971
[TBL] [Abstract][Full Text] [Related]
18. One-electron reduction of mitomycin c by rat liver: role of cytochrome P-450 and NADPH-cytochrome P-450 reductase.
Vromans RM; van de Straat R; Groeneveld M; Vermeulen NP
Xenobiotica; 1990 Sep; 20(9):967-78. PubMed ID: 2122607
[TBL] [Abstract][Full Text] [Related]
19. Reductive metabolism and protein binding of chromium(VI) by P450 protein enzymes.
Mikalsen A; Alexander J; Wallin H; Ingelman-Sundberg M; Andersen RA
Carcinogenesis; 1991 May; 12(5):825-31. PubMed ID: 1903091
[TBL] [Abstract][Full Text] [Related]
20. 3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Fuchs T; Chowdhury G; Barnes CL; Gates KS
J Org Chem; 2001 Jan; 66(1):107-14. PubMed ID: 11429885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
